A 3 Year Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment
Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether treatment with the investigational drug
ladostigil will delay the onset of Alzheimer's disease(AD) in patients with Mild Cognitive
Impairment (MCI). MCI is now recognized as a precursor to AD and clinical tools are available
to assess cognitive performance at this earlier stage. Ladostigil is currently under
investigation for the treatment of AD. In this study, the investigators will be examining
ladostigil at a lower dose level. At this dose level, ladostigil has been shown to reduce
signs of early memory loss in animals. Thus, in this study the investigators are attempting
to determine if earlier invention with a lower dose of ladostigil will significantly reduce
initial memory loss and delay the subsequent progression to more serious cognitive
dysfunction.